Embecta Corp./$EMBC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Ticker
$EMBC
Sector
Primary listing
Employees
2,100
Headquarters
Website
Embecta Corp. Metrics
BasicAdvanced
$799M
9.62
$1.42
1.08
$0.60
4.39%
Price and volume
Market cap
$799M
Beta
1.08
52-week high
$21.23
52-week low
$9.20
Average daily volume
334K
Dividend rate
$0.60
Financial strength
Current ratio
2.474
Quick ratio
1.537
Long term debt to equity
-222.207
Total debt to equity
-226.643
Dividend payout ratio (TTM)
41.75%
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
110.9
Gross margin (TTM)
63.38%
Net profit margin (TTM)
7.58%
Operating margin (TTM)
6.69%
Effective tax rate (TTM)
16.65%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
3.44%
Return on equity (TTM)
-11.67%
Valuation
Price to earnings (TTM)
9.621
Price to revenue (TTM)
0.721
Price to book
-1.19
Price to tangible book (TTM)
-1.15
Price to free cash flow (TTM)
6.006
Free cash flow yield (TTM)
16.65%
Free cash flow per share (TTM)
2.276
Dividend yield (TTM)
4.39%
Forward dividend yield
4.39%
Growth
Revenue change (TTM)
-1.47%
Earnings per share change (TTM)
18.26%
3-year revenue growth (CAGR)
-1.56%
3-year earnings per share growth (CAGR)
-37.78%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Bulls say / Bears say
Embecta posted strong third-quarter results, with revenues reaching $295.5 million—an 8.4% increase over the prior year—driven by 11.6% growth in U.S. sales and a 5.0% rise internationally, showing effective commercial execution.
The company's adjusted operating margin expanded to 36.9% in Q3, up from 30.6% a year earlier, demonstrating sound cost control and improved operational efficiency.
Embecta improved its balance sheet by reducing debt by $52.4 million in Q3, reaching $112 million of debt paid down year-to-date and meeting its full-year target a quarter early, increasing financial flexibility.
Nine-month fiscal 2025 revenues declined 2.5% year-over-year to $816.4 million, due to unfavorable volume changes of $31 million and a negative foreign-currency impact of $7 million, indicating continued pressure on revenue.
Embecta narrowed its full-year 2025 revenue guidance to a range of $1.078 billion–$1.085 billion from $1.073 billion–$1.090 billion, reflecting a lower midpoint and less potential upside than previously expected.
Adjusted gross margin fell by 260 basis points year-over-year to 67.2%, down from 69.8%, highlighting margin challenges related to product mix and pricing pressures.
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2025.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Embecta Corp. stock?
Embecta Corp. (EMBC) has a market cap of $799M as of November 11, 2025.
What is the P/E ratio for Embecta Corp. stock?
The price to earnings (P/E) ratio for Embecta Corp. (EMBC) stock is 9.62 as of November 11, 2025.
Does Embecta Corp. stock pay dividends?
Yes, the Embecta Corp. (EMBC) stock pays dividends to shareholders. As of November 11, 2025, the dividend rate is $0.6 and the yield is 4.39%. Embecta Corp. has a payout ratio of 41.75% on a trailing twelve-month basis.
When is the next Embecta Corp. dividend payment date?
The next Embecta Corp. (EMBC) dividend payment date is unconfirmed.
What is the beta indicator for Embecta Corp.?
Embecta Corp. (EMBC) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.